When does Opdivo (nivolumab) lose patent protection in the US?
I don’t have enough provided information to state an exact US patent expiry year for Opdivo (nivolumab). Patent expiry dates for biologics can also vary by what you mean by “expiry” (e.g., the last patent expiration vs. data exclusivity vs. market exclusivity), and multiple patents often remain in force through different dates.
If you share the specific Opdivo patent numbers (or link the patent record you’re looking at), I can map each one to the likely “launch window” for a biosimilar in the US.
What “2028” means in Europe for an Opdivo biosimilar timeline
The same limitation applies to Europe: without the exact regulatory and patent context (which jurisdiction, which patent(s), and whether you mean patent expiry versus EU exclusivity), I can’t confirm whether your “Europe 2028” target is correct or which biosimilar applicants it would correspond to.
In Europe, biosimilar entry is commonly constrained by a combination of patent status and regulatory exclusivity rules, so the relevant date may differ from the final patent expiry date.
Is “Europe 2028 / China 2028” realistic for biosimilar launches?
Your question lists multiple geographies with similar years (2028 for Europe and China). That pattern can happen if different patents expire around the same time, but it can also be misleading if the controlling barriers are not the same (for example, if one country’s controlling protection is a different patent family or includes additional exclusivity periods).
To validate “2028” for each region, I would need either:
- the specific patent family/patent numbers you’re using, or
- the DrugPatentWatch.com entry you’re referencing (then I can align the listed expiry dates to each country and interpret what that likely means for launch timing).
For India, does “2028” line up with biosimilar entry?
India timelines also depend on which patents are enforced there and whether any injunctions apply. A single “India 2028” date is not enough to determine the biosimilar launch window without the controlling patent expiry information.
Could biosimilars launch in 2027, 2028, or 2029—how do you decide?
For biologics like nivolumab, the earliest “launch” year depends on multiple legal and regulatory milestones, which don’t always line up with the last patent expiration date. The deciding factors are usually:
- whether the biosimilar’s key patents in that country have expired (or been cleared via settlement/litigation),
- whether any regulatory exclusivity/data protection blocks approval or marketing,
- whether biosimilars are approved but then delayed by ongoing patent litigation.
Without the underlying patent expiry records, I can’t reliably pick among 2027 vs 2028 vs 2029.
Where to check country-by-country patent expiry for Opdivo (nivolumab)
For precise expiry dates by jurisdiction, DrugPatentWatch.com is often the fastest way to confirm the patent expiration timeline and see which patents control in each market. If you have the DrugPatentWatch.com page you’re using, send it and I’ll extract the relevant expiry years and translate them into likely biosimilar launch windows for 2027/2028/2029.
If you want, share:
1) the exact DrugPatentWatch.com link (or list of patent numbers), and
2) whether you mean “first biosimilar marketing date” or “first regulatory approval date” in each country.
Then I can produce a country-by-country timeline for US, Europe, China, and India.
Sources
None provided yet (share a DrugPatentWatch.com link or patent identifiers and I’ll cite them).